Vipharm S.A.

What Vipharm S.A. does

Vipharm S.A. is a privately-held Polish pharmaceutical company founded in 1998 by doc. dr Wiesław Szelejewski, specializing in the development, production, and commercialization of specialty generic medicines. The company operates across four therapeutic areas — oncology, neurology, psychiatry, and diabetology — organized into three sales divisions: Vipharm Onkologia, Vipharm CNS, and Vipharm Diabetologia. Its product portfolio comprises over 26 registered branded generics covering breast and prostate cancer treatments (Lametta, Atrozol, Binabic, Abiraterone Vipharm, Fulvestrant Vipharm), bone metastases agents (Pamifos, Zomikos), CNS disorders (Fimodigo for multiple sclerosis, Donesyn/Memantine for Alzheimer's, Aropilo/Rasagiline for Parkinson's, Arketis/Olpinat/Bonogren/Risperidon/Asduter for psychiatric conditions), and Type 2 diabetes therapies (Anvildis, Anvildis Duo, Ansifora). Products are priced 20-80% below original branded drugs while maintaining bioequivalence validated through clinical studies conducted under GMP, GLP, and GCP standards.

The company's core technology platform is an in-house R&D department and fully equipped laboratory where approximately 20 specialized teams execute the full drug development cycle from concept to pharmacy registration over a 2-5 year period. Vipharm conducts proprietary pharmaceutical substance development and generates its own bioequivalence data. The company holds multiple EU and Polish government research grants (INNOMED, Applied Research Program) for developing innovative anti-cancer drug technology, neuropathic pain treatments, and multiple sclerosis therapies, with combined project values exceeding 18 million PLN.

Vipharm generates revenue through pharmacy and hospital distribution channels across five markets — Poland as the primary market plus Czech Republic, Slovakia, Hungary, and Germany via wholly-owned subsidiaries established in 2008. Sales are executed through dedicated therapeutic-area sales teams targeting oncologists, neurologists, psychiatrists, diabetologists, and palliative care specialists. The company is a member of the European Generic and Biosimilar Medicines Association (EGA), follows the EGA Code of Conduct, and maintains reimbursement list presence in Poland. Vipharm is led by President Jan Szelejewski and operates with approximately 74 employees from its headquarters in Ożarów Mazowiecki, Poland.

Name

Vipharm S.A.

Legal name

VIPHARM SPÓŁKA AKCYJNA

Website

https://vipharm.com.pl

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

51–100 employees

Short description

Vipharm S.A. is a Polish specialty generic pharmaceutical company founded in 1998 that develops, manufactures, and markets generic medicines across oncology, neurology, psychiatry, and diabetology therapeutic areas, operating in five Central European markets through a physician-focused sales-led model.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

akta.pro secondary industries

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD), Specialty Pharmaceutical Distributors (HLAIAJAB)

Keywords

• Generic pharmaceuticals
• Oncology medications
• Neurology therapeutics
• Diabetes treatments
• Specialty generics

Headquarters

HQ city

Ożarów Mazowiecki

HQ country

Poland

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

1. Generic Pharmaceutical Sales: Vipharm S.A. generates revenue through the development, production, and sale of generic pharmaceutical products. The company focuses on specialist generic medicines in oncology, neurology, psychiatry, and diabetology. Generic products are sold at 20% to 80% lower prices compared to original drugs while maintaining equivalent quality, efficacy, and safety.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Vipharm S.A. develops, manufactures, and markets generic specialty medicines with a therapeutic focus on oncology, neurology, psychiatry, and diabetology. Founded in 1998 in Poland, the company concentrates on providing affordable generic alternatives in specialty therapeutic areas where treatment access and cost can be limiting factors.

Product overview

Vipharm S.A. is a Polish pharmaceutical company that develops, manufactures, and markets generic medications across four therapeutic areas: Oncology, Neurology, Psychiatry, and Diabetology. The product portfolio consists of a comprehensive range of generic drugs organized into three specialized sales divisions: Vipharm Onkologia (oncology and hematology products), Vipharm CNS (central nervous system products for neurology and psychiatry), and Vipharm Diabetologia (diabetes medications). The oncology portfolio includes treatments for breast cancer (Lametta, Atrozol, FULVESTRANT VIPHARM), prostate cancer (Binabic, Abiraterone Vipharm), bone metastases (PAMIFOS, ZOMIKOS), cancer cachexia (MEGALIA), iron overload (Exferana), dry mouth (Fomukal), neuropathic pain (NAXALGAN), and essential thrombocythemia (Anagrelide Vipharm). The CNS portfolio covers Alzheimer's disease (DONESYN, MEMANTINE VIPHARM), Parkinson's disease (AROPILO, AROPIRO SR, RASAGILINE VIPHARM), multiple sclerosis (FIMODIGO), schizophrenia (OLPINAT, BONOGREN, BONOGREN SR, RISPERIDON VIPHARM, ASDUTER), bipolar disorder (BONOGREN, BONOGREN SR, ASDUTER), and depression/anxiety (ARKETIS). The diabetology portfolio includes DPP-4 inhibitors (ANVILDIS, ANSIFORA) and combination therapies (ANVILDIS DUO). All products are manufactured and registered in accordance with EU pharmaceutical standards and Good Manufacturing Practices.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• Generic drugs available at 20-80% lower prices compared to original branded medications while maintaining equivalent quality, efficacy, and safety.
• +1 more outcomes

Named customers6 records

Segments5 records

Ideal customer profiles1 record

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

Feature3 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Instytut Biotechnologii i Antybiotyków (Institute of Biotechnology and Antibiotics)coreStrategic or Co-development Partner · 1 June 2014Partner in the Applied Research Program project for developing innovative technology for manufacturing a neuropathic pain treatment drug. Project value: 3,295,849.00 PLN with 2,098,764.00 PLN in funding.
• Instytut Farmaceutyczny (Pharmaceutical Institute)coreStrategic or Co-development Partner · 1 January 2014Research consortium partner in the INNOMED program for developing innovative anticancer drug technology inhibiting androgen biosynthesis. Instytut Farmaceutyczny is a leading scientific research center in Poland with over 50 years of experience, serving as the research partner for Vipharm S.A.
• Polskie Towarzystwo Medycyny Paliatywnej (Polish Palliative Medicine Society)minorOthers · 1 January 2009Supporting member since 2009. Partnership focused on supporting palliative medicine education and patient care initiatives.
• Stowarzyszenie Klub Kobiet po Mastektomii Amazonki (Amazonki Breast Cancer Survivors Association)coreStrategic or Co-development PartnerPartnership with elite patient organization supporting breast cancer patients through psychological and practical support, early detection awareness, rehabilitation, patient rights education, and access to modern treatments. Vipharm supports volunteering and organizes psycho-oncology workshops for both patients and doctors.
• European Generic and Biosimilar Medicines Association (EGA)minorOthersVipharm S.A. is a member of EGA, the European association of generic and biosimilar medicines manufacturers. The company has signed and implemented the Code of Conduct for interactions with healthcare professionals, and publishes transparency reports on support provided to healthcare professionals and patient organizations since 2017.
• Narodowe Centrum Badań i Rozwoju (National Centre for Research and Development)coreStrategic or Co-development PartnerCollaboration under the Applied Research Program for developing innovative pharmaceutical technologies. Vipharm has received multiple grants through this partnership for R&D projects in oncology and CNS areas.

Scale indicators4 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Tarchomińskie Zakłady Farmaceutyczne Polfa (TZF Polfa): Polish pharmaceutical manufacturer with generic portfolio spanning CNS, cardiology, and other therapeutic areas. Directly comparable as a domestic Polish generic manufacturer serving similar pharmacy and hospital channels.
• Gedeon Richter: Hungarian-headquartered pharmaceutical company with strong CNS, women's health, and generic portfolio across Central Europe. Directly competes in similar therapeutic areas (CNS especially) and geographies overlapping with Vipharm's Hungarian and broader CEE operations.
• KRKA: Slovenian generic pharmaceutical manufacturer with strong presence across Central and Eastern Europe. Directly comparable as a regional generic player developing specialty generics across CNS, oncology, and metabolic disease therapeutic areas.
• Polpharma: Poland's largest generic pharmaceutical manufacturer and a direct domestic peer. Both develop, manufacture, and market generic medicines in Poland and select Central European markets, serving similar therapeutic areas and pharmacy/hospital channels.
• Zentiva: Central European-based generic pharmaceutical company headquartered in Prague, operating across Czech Republic, Slovakia, Hungary, Germany and other markets. Directly comparable business model of developing and distributing specialty generics in cardiology, CNS, oncology, and other specialty areas.
• Alvogen: Central and Eastern European-focused generic pharmaceutical company with presence in oncology, CNS, and other specialty areas. Comparable as a regional specialty generic player operating in overlapping Central European markets.

Broad incumbents

• Viatris: Global pharmaceutical company formed by the merger of Mylan and Upjohn, with substantial generic portfolio across CNS, oncology, and diabetes. Competes broadly with Vipharm in Central European generic markets.
• Sandoz (Novartis): Global leader in generic and biosimilar medicines with extensive CNS, oncology, and metabolic disease portfolios. Operates as a broad incumbent competitor in Vipharm's markets at significantly larger scale.
• Stada Arzneimittel: Large European generic pharmaceutical company with broad portfolio across multiple therapeutic areas including CNS and oncology. Operates as a broader incumbent in the same generic pharma space across Central Europe, though at significantly larger scale than Vipharm.
• Teva Pharmaceutical Industries: World's largest generic pharmaceutical manufacturer with extensive CNS, oncology, and specialty portfolios. Competes with Vipharm on multiple molecules in Poland and other Central European markets as a broad incumbent.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/vipharm

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vipharm S.A.